AL SJR76

Urges the Food and Drug Administration to grant accelerated approval for the drug eteplirsen to treat Duchenne Muscular Dystrophy (DMD) under the Food and Drug Administration Safety and Innovation Act of 2012 expedited approval pathways.

Identifies DMD as the most fatal genetic disorder diagnosed in childhood, affecting approximately one in every 3,500 live male births or 20,000 new cases annually.

Notes that DMD causes progressive loss of strength and muscle weakness, typically requiring wheelchair use by age 12, serious heart and lung issues as teenagers, and death in the twenties.

States that scientific and clinical data support the successful use of eteplirsen and a new drug application has been submitted to the FDA.

Directs copies of the resolution be provided to the FDA Commissioner and each member of the Alabama Congressional Delegation.